BIOTRONIK and Philips expand care for out-of-hospital cardiology labs with new strategic alliance
BIOTRONIK, a leading global medical device company with products and services that improve the lives of patients suffering from cardiovascular and endovascular diseases, today announced it has teamed up with Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, to expand the range of cardiovascular devices available for Philips SymphonySuite customers.
Philips SymphonySuite is the market-leading solution for opening and expanding cardiovascular office-based labs (OBLs) and ambulatory surgery centers (ASCs), and includes a full range of high-performing, highly specialized equipment and devices, personalized services, financing options, site-planning, ongoing operational support, and more.
With more procedures moving to out-of-hospital care settings such as OBLs and ASCs, the combination of Philips’ SymphonySuite offerings and BIOTRONIK’s full range of cardiac rhythm management (CRM), cardiovascular intervention (CVI), and peripheral vascular intervention (PVI) product portfolio provides more options to individualize patient care and create treatment strategies for low-risk cardiac procedures performed in these settings.
Societal, provider and state regulation continue to support this shift in care settings due to patient demand, improvements in medical technology, as well as financial and operational benefits. Out-of-hospital care settings increase access to care and allow for a more personalized patient experience with a lower risk of hospital-acquired infections for patients. In general, procedures performed in out-of-hospital settings have lower overhead and capital costs — these savings help drive lower costs for patients.
“Philips is committed to expanding access to care through its innovative solutions and BIOTRONIK’s alliance adds additional devices, including a cardiac rhythm management portfolio, to SymphonySuite,” said Chris DeCarolis, Head of Procedural Solutions for Image Guided Therapy at Philips. “We will continue to evolve to stay ahead of the needs of physicians and patients and provide cardiovascular equipment, devices and services in out-of-hospital settings while reducing cost pressures via innovative business models.”
Atul Suri, Vice President of Commercial Excellence at BIOTRONIK, added: “Through BIOTRONIK’s innovative cardiovascular technologies, we’re committed to partnering with outpatient sites of service. Aligning with Philips will allow us to bring greater value to our outpatient customers, particularly those with capital equipment needs at ASC and OBL facilities.”
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.